de.mpg.escidoc.pubman.appbase.FacesBean
English
 
Help Guide Disclaimer Contact us Login
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Clinical and molecular diagnosis of multiple endocrine neoplasia type 1

MPS-Authors

Karges,  W
Max Planck Institute of Psychiatry, Max Planck Society;

Schaaf,  L
Max Planck Institute of Psychiatry, Max Planck Society;

Dralle,  H
Max Planck Institute of Psychiatry, Max Planck Society;

Boehm,  BO
Max Planck Institute of Psychiatry, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Karges, W., Schaaf, L., Dralle, H., & Boehm, B. (2002). Clinical and molecular diagnosis of multiple endocrine neoplasia type 1. Langenbecks Archives of Surgery, 386(8), 547-552.


Cite as: http://hdl.handle.net/11858/00-001M-0000-000E-A237-D
Abstract
Multiple endocrine neoplasia type 1 (MEN1) is a classic hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine neoplasias and hormone excess syndromes. The disease is caused by inactivating mutations of the MEN1 tumor suppressor gene, detectable in >95% of MEN1 families. The distinction of MEN1- associated tumors from sporadic neuroendocrine neoplasias is clinically important for providing optimal surgical and medical therapy, appropriate clinical follow-up, and counsel for affected patients and their families. Since MEN1 gene analysis became available in 1997, new diagnostic approaches have evolved in clinical management, to be reviewed in this article. Genetic screening of MEN1 families will allow definition of individual disease risk at a preclinical stage, thus helping to allocate medical resources and treatment as individually needed. These new diagnostic approaches are expected to reduce MEN1-associated morbidity and mortality, health care expenses, and psychological disease burde